Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 25, 2026

Principal Financial Group Inc (PFG) Q1 2026 Earnings Call Highlights: Strong EPS Growth and ...

View original at finance.yahoo.com
“RIS Pre-tax Operating Earnings: $318 million, a 4% increase year-over-year.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Adjusted Non-GAAP EPS grew 13% in Q1 2026, surpassing the high end of their target range

    60% confidence
  • Investment Management Gross Sales reached a record $37 billion in Q1 2026, a 21% year-over-year increase, driven by strong demand for private markets and active ETF business

    60% confidence
  • Non-GAAP Operating ROE improved 140 basis points to 16.1% in Q1 2026

    60% confidence
  • Specialty Benefits Premium Fees grew 4% year-over-year in Q1 2026

    60% confidence
  • Life Insurance Pre-tax Operating Earnings were $37 million in Q1 2026, a $23 million increase year-over-year

    60% confidence
  • International Pension AUM grew 20% year-over-year to $160 billion in Q1 2026

    60% confidence
  • Private Markets AUM grew 11% year-over-year in Q1 2026

    60% confidence
  • PFG raised its common stock dividend for the 12th consecutive quarter with an 8% increase on both a quarterly and trailing 12-month basis

    60% confidence
  • Operating margin expanded 190 basis points to 30% in Q1 2026

    60% confidence
  • Benefits and Protection Pre-tax Operating Earnings were $177 million in Q1 2026, a 41% increase year-over-year

    60% confidence
  • Specialty Benefits sales grew 24% year-over-year in Q1 2026

    60% confidence
  • DCIO sales reached $2 billion in Q1 2026 and nearly $8 billion over the trailing 12 months

    60% confidence
  • Excess and available capital exceeded $1.4 billion as of Q1 2026

    60% confidence
  • RIS Pre-tax Operating Earnings were $318 million in Q1 2026, a 4% increase year-over-year

    60% confidence
  • Principal Asset Management earnings grew 10% year-over-year in Q1 2026

    60% confidence
  • Non-GAAP Operating Earnings were $456 million in Q1 2026, a 10% increase year-over-year

    60% confidence
  • Total retirement transfer deposits reached $12 billion in Q1 2026, a 35% year-over-year increase, reflecting strong business retention and new client acquisition

    60% confidence
  • PFG returned approximately $375 million of capital to shareholders in Q1 2026, including $200 million in share repurchases

    60% confidence
  • Recurring deposits grew 7% year-over-year in Q1 2026

    60% confidence
  • Non-GAAP Operating EPS was $2.07 per share in Q1 2026, a 14% increase year-over-year

    60% confidence
  • Total company managed AUM reached $770 billion in Q1 2026, up 7% year-over-year

    60% confidence
  • Business Market Life Premium and Fees grew 15% year-over-year in Q1 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com